BR0112543A - Derivados hidrazìdicos do ácido pirrolidino-2-carboxìlico para uso como inibidores de metaloproteases - Google Patents

Derivados hidrazìdicos do ácido pirrolidino-2-carboxìlico para uso como inibidores de metaloproteases

Info

Publication number
BR0112543A
BR0112543A BR0112543-5A BR0112543A BR0112543A BR 0112543 A BR0112543 A BR 0112543A BR 0112543 A BR0112543 A BR 0112543A BR 0112543 A BR0112543 A BR 0112543A
Authority
BR
Brazil
Prior art keywords
derivatives
carboxylic acid
hydrazic
pyrrolidine
metalloprotease inhibitors
Prior art date
Application number
BR0112543-5A
Other languages
English (en)
Original Assignee
Hoffmannnn La Roche Ag F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmannnn La Roche Ag F filed Critical Hoffmannnn La Roche Ag F
Publication of BR0112543A publication Critical patent/BR0112543A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"DERIVADOS HIDRAZìDICOS DO áCIDO PIRROLIDINO-2-CARBOXìLICO PARA USO COMO INIBIDORES DE METALOPROTEASES". A presente invenção refere-se a compostos da fórmula (I), onde R^ 1^, R^ 2^, R^ 3^, R^ 4^, R^ 5^ e X são como definidos na descrição e nas reivindicações, e seus ésteres e/ou seus sais de uso farmacêutico. Os compostos são úteis como inibidores de metaloproteases, como por exemplo, proteases de zinco, particularmente hidrolases de zinco, e que são eficazes no tratamento de estados doentios associados à vasoconstrição com ocorrências crescentes.
BR0112543-5A 2000-07-19 2001-07-11 Derivados hidrazìdicos do ácido pirrolidino-2-carboxìlico para uso como inibidores de metaloproteases BR0112543A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00114948 2000-07-19
PCT/EP2001/007995 WO2002006224A1 (en) 2000-07-19 2001-07-11 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
BR0112543A true BR0112543A (pt) 2003-07-01

Family

ID=8169225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112543-5A BR0112543A (pt) 2000-07-19 2001-07-11 Derivados hidrazìdicos do ácido pirrolidino-2-carboxìlico para uso como inibidores de metaloproteases

Country Status (18)

Country Link
US (1) US6444829B1 (pt)
EP (1) EP1317428B1 (pt)
JP (1) JP2004504298A (pt)
KR (1) KR100580056B1 (pt)
CN (1) CN1318402C (pt)
AR (1) AR033543A1 (pt)
AT (1) ATE323673T1 (pt)
AU (1) AU2001276396A1 (pt)
BR (1) BR0112543A (pt)
CA (1) CA2415665A1 (pt)
DE (1) DE60118941T2 (pt)
ES (1) ES2261443T3 (pt)
MX (1) MXPA03000363A (pt)
PA (1) PA8522401A1 (pt)
PE (1) PE20020339A1 (pt)
UY (1) UY26844A1 (pt)
WO (1) WO2002006224A1 (pt)
ZA (1) ZA200300172B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
CN103145572A (zh) * 2013-03-20 2013-06-12 康化(上海)新药研发有限公司 天然产物氯化γ-正缬氨酸盐酸盐的不对称合成方法
CN105712910B (zh) * 2016-03-08 2017-06-06 北京化工大学 (n‑芳基亚磺酰基)磺酰肼及其制备方法
WO2021029158A1 (ja) * 2019-08-09 2021-02-18 サンアプロ株式会社 スルホンアミド化合物、非イオン系光酸発生剤、およびフォトリソグラフィー用樹脂組成物
CN113030292A (zh) * 2021-01-29 2021-06-25 京博农化科技有限公司 一种对三氟甲氧基苯胺基甲酰肼含量的分析方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493333A (en) * 1893-03-14 Air-heating furnace
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
IL117440A0 (en) * 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process
ES2201318T3 (es) * 1996-08-28 2004-03-16 THE PROCTER & GAMBLE COMPANY Inhibidores de metaloproteasas de aminas ciclicas substituidas.

Also Published As

Publication number Publication date
WO2002006224A1 (en) 2002-01-24
DE60118941D1 (de) 2006-05-24
UY26844A1 (es) 2002-01-31
EP1317428A1 (en) 2003-06-11
MXPA03000363A (es) 2003-05-27
CN1318402C (zh) 2007-05-30
AU2001276396A1 (en) 2002-01-30
PA8522401A1 (es) 2002-09-30
EP1317428B1 (en) 2006-04-19
PE20020339A1 (es) 2002-04-23
CN1443163A (zh) 2003-09-17
CA2415665A1 (en) 2002-01-24
ATE323673T1 (de) 2006-05-15
ZA200300172B (en) 2004-04-07
US20020040048A1 (en) 2002-04-04
AR033543A1 (es) 2003-12-26
ES2261443T3 (es) 2006-11-16
DE60118941T2 (de) 2006-12-21
KR20030024797A (ko) 2003-03-26
KR100580056B1 (ko) 2006-05-12
US6444829B1 (en) 2002-09-03
JP2004504298A (ja) 2004-02-12

Similar Documents

Publication Publication Date Title
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BR0015254A (pt) Derivados de carbamoiloxialquil-azólio substituìdos em n
BR0114917A (pt) Inibidores de pirimidina-2,4,6-triona metaloproteinase
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0109353A (pt) Cadeia lateral heterocìclica contendo inibidores de metaloprotease
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR9811730A (pt) Derivados de n-aroilfenilalanina
BR0016195A (pt) 4-pirimidinil-n-acil-l-fenilalaninas
BR0211863A (pt) 1-alquil ou 1-cicloalquiltriazolo[4,3a]quinazolin-5-onas como inibidores da fosfodiesterase
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BRPI0607019A2 (pt) compostos que inibem a atividade de beta -secretase e métodos de uso dos mesmos
BR0010555A (pt) Inibidores de neuraminidases
BR9915013A (pt) Composto, uso dos mesmos, processo para preparar os mesmos, droga, e, método para detecção in vitro para inibidores parp
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
BRPI0507972A (pt) composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BR0316091A (pt) Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
BR0206501A (pt) Inibidores de cruzipaìna e outras cisteìna proteases
BR0112580A (pt) Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR9815784A (pt) Benzoxazinonas/benzotiazinonas como inibidores de protease de serina
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2021 DE 29/09/2009.